by Peter Ciszewski | Mar 19, 2018
Justin Fallon, PhD is the Scientific Founder and Director of Tivorsan Pharmaceuticals, discusses Biglycan as an emerging therapy for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Biglycan is a small, naturally occurring extracellular matrix...
by Peter Ciszewski | Mar 19, 2018
Dr. Daniel Alkon of Neurotrope BioSciences discusses the importance of partnering with Advocacy Groups such as the Fragile X Foundation for company. Neurotrope has reached out to advocacy groups for their clinical trial strategy for Bryostatin 1 for the treatment of...
by Peter Ciszewski | Feb 16, 2018
The 2018 BIO CEO & Investor Conference took place in New York City on February 12-13 in New York City. This Conference remains one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies....
by Peter Ciszewski | Feb 7, 2018
Roxana Sulica, MD, Associate Professor, Department of Medicine and Director, Pulmonary Hypertension at NYU Langone in New York City discusses some of the emerging tretment options for pulmonary arterial hypertension (PAH). One of these emerging therapies is the...
by Peter Ciszewski | Feb 7, 2018
Sam Falsetti, PhD of Cambridge Biomarketing discusses the role of rare disease advocacy groups.
